Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 13/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2236026 | 1.00 | BDKRB1 (0.49) | BDKRB1NPC1RAB9ANR1H4GSK3B | |
| SCHEMBL12346958 | 0.96 | BDKRB1 (0.53) | BDKRB1NPC1RAB9ANR1H4CACNA2D1 | |
| Trifluoroacetic Acid SCHEMBL2240775 | 0.93 | BDKRB1 (0.41) | BDKRB1NPC1RAB9ANR1H4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2238219 | 0.92 | BDKRB1 (0.41) | BDKRB1NPC1RAB9ANR1H4GSK3B | |
| Trifluoroacetic Acid SCHEMBL2235468 | 0.90 | BDKRB1 (0.38) | BDKRB1NR1H4CACNA1GKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2236920 | 0.89 | HRH3 (0.39) | BDKRB1NR1H4CACNA1GKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2237764 | 0.89 | BDKRB1 (0.39) | BDKRB1NR1H4CACNA1GKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2237731 | 0.88 | BDKRB1 (0.38) | BDKRB1NR1H4GSK3BCACNA1GKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2238848 | 0.88 | BDKRB1 (0.38) | BDKRB1NR1H4 | |
| Trifluoroacetic Acid SCHEMBL2239561 | 0.88 | BDKRB1 (0.39) | BDKRB1NR1H4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | BDKRB1 1/4885NPC1 2189/4885RAB9A 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.